Dr. S. Venkatesan MD

NOVEMBER 21, 2023

ASDs are classically oval, but devices are typically circular.(Exact Incidence of ovoid ASD is not known. but it easily exceed 50 %.(Recall, the embryologically ill-fated hole expands around the fossa ovalis not circularis ) Do we have Oval devices ? I think, we don’t have one. Please check from this list , a good document on ASD device implantation from Poland Source : Grygier M, S.

Congenital Heart Disease 52

Congenital Heart Disease Document Cardiovascular Interventions Congenital 52

Dr. Paddy Barrett

NOVEMBER 21, 2023

“The decisive question for man is: Is he related to something infinite or not? That is the telling question of his life.” Carl Jung The answer to this question for those who came before us was clear. It was an emphatic yes. For with a God, our connection to the infinite was obvious. With this relationship, a set of beliefs and values were laid out that made ‘ knowing what to do’ with your life very obvious.

Research 52

Research 52

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

In the latest years several studies described the impact of repetitive/intermittent i.v levosimendan treatment in the management of advanced heart failure. For this updated review we systematically searched the literature for clinical trials, registries, and real-world data, and identified 31 studies that we commented in a narrative review: 3814 patients were described, of whom 1744 were treated repetitively with levosimendan.

Heart Failure 40

Heart Failure Article 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 21, 2023

Stroke: Vascular and Interventional Neurology, Ahead of Print. BACKGROUNDAs the number of thrombectomy passes increases during endovascular therapy (EVT) for acute stroke, neurointerventionalists must weigh the risks of potential complications against the risk of failing to recanalize the affected vessel. Thus, we investigated the effectiveness and safety of EVT for patients with acute stroke in which ≥5 EVT passes were performed.METHODSThis retrospective cohort study from January 2013 to Decemb

Outcomes 40

Outcomes Stroke Strokes Hemorrhage 40

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

Abstract: Dapagliflozin (DAPA) is a novel oral hypoglycemic agent, and there is increasing evidence that DAPA has a protective effect against cardiovascular disease. The study aimed to investigate how DAPA inhibits cardiac hypertrophy and explore its potential mechanisms. By continuously infusing isoprenaline (ISO) for two weeks using a subcutaneous osmotic pump, a cardiac hypertrophic model was established in male C57BL/6 mice.

Cardiovascular Disease 40

Cardiovascular Disease Article 40

Stroke Journal

NOVEMBER 21, 2023

Stroke, Ahead of Print. Stroke is a leading cause of death and disability in the United States and worldwide, necessitating comprehensive efforts to optimize stroke risk factor management. Health disparities in stroke incidence, prevalence, and risk factor management persist among various race/ethnic, geographic, and socioeconomic populations and negatively impact stroke outcomes.

Health Disparities 40

Health Disparities Risk Factors Stroke Strokes 40

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR. However, few studies have investigated the prognostic effect of preoperative antiplatelet therapy in patients undergoing TAVR.

Aortic valve 40

Aortic valve Aortic TAVR Myocardial Infarction 40

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

To systematically evaluate the efficacy and safety of renin-angiotensin inhibitors (RASIs) and angiotensin receptor neprilysin inhibitors (ARNI) in preventing the recurrence of atrial fibrillation after atrial fibrillation ablation, we have written this meta-analysis. To systematically evaluate the efficacy and safety of renin-angiotensin inhibitors (RASIs) and angiotensin receptor neprilysin inhibitors (ARNI) in preventing the recurrence of atrial fibrillation after atrial fibrillation ablation

Atrial Fibrillation 40

Atrial Fibrillation Ablation Research Article 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 21, 2023

In this large substudy of the AWARE Trial, a high-power short-duration (HPSD) radiofrequency ablation strategy was found to be similarly effective as a low-power long-duration strategy with no difference in time to first recurrence of any AF lasting ≥30 s. Procedural were substantially reduced with HPSD ablation with no significant difference in overall complication rates.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

HeartRhythm

NOVEMBER 21, 2023

It was the spring of 1999. An eager electrophysiology fellow was sitting next to his mentor, on the plane ride back from the American College of Cardiology Scientific Sessions, putting together slides on highlights of the meeting. The results of the Multicenter Unsustained Tachycardia Trial (MUSTT) were presented at the late breaking sessions. His mentor, a pillar of science and investigation, looked over his shoulder, and much to the fellow’s surprise, stated “how many trials do we need that sa

Arrhythmia 40

Arrhythmia Electrophysiology Tachycardia 40

European Journal of Heart Failure

NOVEMBER 21, 2023

Abstract Background Cimlanod is a nitroxyl donor with vasodilator properties. Methods In this randomised, double-blind, mechanistic, cross-over trial, twenty-one patients with left ventricular ejection fraction <45%, increased plasma concentrations of NT-proBNP and receiving loop diuretics were given, on separate study days, either an eight-hour intravenous (IV) infusion of cimlanod (12 μg/kg/min) or placebo.

Heart Failure 40

Heart Failure Blood Pressure Article Research 40

Becker's Hospital Review - Cardiology

NOVEMBER 21, 2023

Kids and teens who have been treated for multisystem inflammatory syndrome, or MIS-C, after a COVID-19 infection should be given a follow-up cardiac assessment , according to experts at Children's Hospital Los Angeles.

COVID-19 40

COVID-19 Hospital 40

European Journal of Heart Failure

NOVEMBER 21, 2023

Neuropeptide Y in heart failure and the association with outcomes Abstract Aims Neuropeptide Y (NPY) is the most abundant neuropeptide found in the heart and is released alongside norepinephrine following prolonged sympathetic activation, a process that is implicated in the pathophysiology of heart failure (HF). In patients with severely impaired left ventricular ejection fraction (LVEF) undergoing cardiac resynchronization therapy, higher levels of NPY measured in coronary sinus blood, are asso

Heart Failure 40

Heart Failure Outcomes Hospital Research 40

JAMA Cardiology

NOVEMBER 21, 2023

This cohort study assesses outcomes in patients with pulmonary embolism using high-sensitivity vs conventional troponin I.

Embolism 40

Embolism Pulmonary Outcomes 40

European Journal of Heart Failure

NOVEMBER 21, 2023

Low Blood Pressure & Heart Failure in SwedeHF: The heightened risk associated with lower systolic blood pressure (SBP) is reduced when higher doses of heart failure medications are used. Increasing medication doses, even when leading to a decrease in SBP, does not correlate with an elevated risk, indicating that low SBP should not inhibit the optimization of heart failure therapy.

Heart Failure 40

Heart Failure Blood Pressure Hospital Outcomes 40

Stroke Journal

NOVEMBER 21, 2023

Stroke, Ahead of Print. Patent foramen ovale (PFO) is frequently identified in young patients with ischemic stroke. Randomized controlled trials provide robust evidence supporting PFO closure in selected patients with cryptogenic ischemic stroke; however, several questions remain unanswered. This report summarizes current knowledge on the epidemiology of PFO-associated stroke, the role of PFO as a cause of stroke, and anatomic high-risk features.

Stroke 40

Stroke Strokes Atrial Fibrillation Technology 40

JAMA Cardiology

NOVEMBER 21, 2023

This comparative effectiveness study, a prespecified analysis from the MASTER DAPT trial, reports sex differences and the association of sex with outcomes among patients with high bleeding risk treated with an abbreviated vs standard dual antiplatelet therapy regimen.

Outcomes 40

Outcomes 40